nodes	percent_of_prediction	percent_of_DWPC	metapath
Sitaxentan—CYP2C9—Estropipate—osteoporosis	0.0872	0.16	CbGbCtD
Sitaxentan—CYP2C19—Cholecalciferol—osteoporosis	0.054	0.0991	CbGbCtD
Sitaxentan—CYP3A4—Estropipate—osteoporosis	0.0507	0.093	CbGbCtD
Sitaxentan—CYP3A4—Calcitriol—osteoporosis	0.0507	0.093	CbGbCtD
Sitaxentan—CYP2C9—Cholecalciferol—osteoporosis	0.0449	0.0824	CbGbCtD
Sitaxentan—CYP2C19—Estradiol—osteoporosis	0.0436	0.0798	CbGbCtD
Sitaxentan—CYP3A4—Ergocalciferol—osteoporosis	0.0405	0.0743	CbGbCtD
Sitaxentan—CYP2C9—Estradiol—osteoporosis	0.0362	0.0664	CbGbCtD
Sitaxentan—CYP3A4—Raloxifene—osteoporosis	0.0338	0.062	CbGbCtD
Sitaxentan—CYP3A4—Ethinyl Estradiol—osteoporosis	0.0327	0.0599	CbGbCtD
Sitaxentan—CYP3A4—Cholecalciferol—osteoporosis	0.0261	0.0479	CbGbCtD
Sitaxentan—CYP3A4—Conjugated Estrogens—osteoporosis	0.024	0.044	CbGbCtD
Sitaxentan—CYP3A4—Estradiol—osteoporosis	0.0211	0.0386	CbGbCtD
Sitaxentan—EDNRA—GPCR downstream signaling—CALCR—osteoporosis	0.000363	0.00542	CbGpPWpGaD
Sitaxentan—CYP3A4—Drug Induction of Bile Acid Pathway—VDR—osteoporosis	0.000359	0.00536	CbGpPWpGaD
Sitaxentan—EDNRB—Peptide ligand-binding receptors—POMC—osteoporosis	0.000352	0.00526	CbGpPWpGaD
Sitaxentan—CYP2C9—Phase 1 - Functionalization of compounds—CYP27A1—osteoporosis	0.00035	0.00523	CbGpPWpGaD
Sitaxentan—EDNRB—GPCR ligand binding—CALCA—osteoporosis	0.000344	0.00514	CbGpPWpGaD
Sitaxentan—EDNRA—GPCR ligand binding—PTH—osteoporosis	0.000337	0.00504	CbGpPWpGaD
Sitaxentan—EDNRA—Signaling by GPCR—PTH1R—osteoporosis	0.00033	0.00492	CbGpPWpGaD
Sitaxentan—EDNRA—Signaling by GPCR—CALCR—osteoporosis	0.00033	0.00492	CbGpPWpGaD
Sitaxentan—EDNRA—GPCR ligand binding—CNR2—osteoporosis	0.000329	0.00491	CbGpPWpGaD
Sitaxentan—CYP2C9—Nuclear Receptors in Lipid Metabolism and Toxicity—VDR—osteoporosis	0.000312	0.00467	CbGpPWpGaD
Sitaxentan—EDNRB—Gastrin-CREB signalling pathway via PKC and MAPK—IL6R—osteoporosis	0.000311	0.00465	CbGpPWpGaD
Sitaxentan—EDNRA—GPCR ligand binding—WNT1—osteoporosis	0.000309	0.00462	CbGpPWpGaD
Sitaxentan—EDNRB—Signaling Pathways—SOST—osteoporosis	0.000301	0.00449	CbGpPWpGaD
Sitaxentan—EDNRA—GPCR downstream signaling—MGLL—osteoporosis	0.000288	0.00431	CbGpPWpGaD
Sitaxentan—CYP3A4—Cytochrome P450 - arranged by substrate type—CYP27A1—osteoporosis	0.000285	0.00426	CbGpPWpGaD
Sitaxentan—CYP3A4—Oxidation by Cytochrome P450—CYP27A1—osteoporosis	0.000281	0.0042	CbGpPWpGaD
Sitaxentan—EDNRA—GPCR ligand binding—PTHLH—osteoporosis	0.00028	0.00418	CbGpPWpGaD
Sitaxentan—EDNRB—Signaling Pathways—PTH1R—osteoporosis	0.000272	0.00406	CbGpPWpGaD
Sitaxentan—EDNRB—Signaling Pathways—CALCR—osteoporosis	0.000272	0.00406	CbGpPWpGaD
Sitaxentan—CYP3A4—Farnesoid X Receptor  Pathway—IRS2—osteoporosis	0.000268	0.00401	CbGpPWpGaD
Sitaxentan—EDNRB—GPCR downstream signaling—PTH—osteoporosis	0.000266	0.00398	CbGpPWpGaD
Sitaxentan—EDNRA—Signaling by GPCR—MGLL—osteoporosis	0.000262	0.00391	CbGpPWpGaD
Sitaxentan—EDNRB—GPCR downstream signaling—CNR2—osteoporosis	0.00026	0.00388	CbGpPWpGaD
Sitaxentan—EDNRA—Peptide ligand-binding receptors—POMC—osteoporosis	0.000252	0.00377	CbGpPWpGaD
Sitaxentan—CYP2C19—Cytochrome P450 - arranged by substrate type—CYP19A1—osteoporosis	0.000249	0.00372	CbGpPWpGaD
Sitaxentan—EDNRA—GPCR ligand binding—CALCA—osteoporosis	0.000246	0.00368	CbGpPWpGaD
Sitaxentan—CYP2C19—Oxidation by Cytochrome P450—CYP19A1—osteoporosis	0.000246	0.00367	CbGpPWpGaD
Sitaxentan—EDNRB—Signaling by GPCR—PTH—osteoporosis	0.000242	0.00361	CbGpPWpGaD
Sitaxentan—EDNRB—Class A/1 (Rhodopsin-like receptors)—POMC—osteoporosis	0.000236	0.00353	CbGpPWpGaD
Sitaxentan—EDNRB—Signaling by GPCR—CNR2—osteoporosis	0.000236	0.00352	CbGpPWpGaD
Sitaxentan—CYP2C19—Arachidonic acid metabolism—GPX1—osteoporosis	0.000234	0.0035	CbGpPWpGaD
Sitaxentan—CYP3A4—Phase 1 - Functionalization of compounds—CYP27A1—osteoporosis	0.000231	0.00345	CbGpPWpGaD
Sitaxentan—CYP2C9—Cytochrome P450 - arranged by substrate type—CYP19A1—osteoporosis	0.000227	0.00339	CbGpPWpGaD
Sitaxentan—CYP2C9—Oxidation by Cytochrome P450—CYP19A1—osteoporosis	0.000224	0.00335	CbGpPWpGaD
Sitaxentan—EDNRA—Gastrin-CREB signalling pathway via PKC and MAPK—IL6R—osteoporosis	0.000223	0.00333	CbGpPWpGaD
Sitaxentan—EDNRB—Signaling by GPCR—WNT1—osteoporosis	0.000222	0.00331	CbGpPWpGaD
Sitaxentan—EDNRB—GPCR downstream signaling—PTHLH—osteoporosis	0.000221	0.0033	CbGpPWpGaD
Sitaxentan—EDNRB—Signaling Pathways—MGLL—osteoporosis	0.000216	0.00323	CbGpPWpGaD
Sitaxentan—EDNRA—Signaling Pathways—SOST—osteoporosis	0.000215	0.00322	CbGpPWpGaD
Sitaxentan—CYP2C9—Arachidonic acid metabolism—GPX1—osteoporosis	0.000214	0.00319	CbGpPWpGaD
Sitaxentan—EDNRB—Signaling Pathways—LRP5—osteoporosis	0.000211	0.00315	CbGpPWpGaD
Sitaxentan—CYP3A4—Nuclear Receptors in Lipid Metabolism and Toxicity—VDR—osteoporosis	0.000206	0.00308	CbGpPWpGaD
Sitaxentan—CYP2C19—Biological oxidations—CYP27A1—osteoporosis	0.000204	0.00305	CbGpPWpGaD
Sitaxentan—CYP2C19—Phase 1 - Functionalization of compounds—CYP19A1—osteoporosis	0.000202	0.00301	CbGpPWpGaD
Sitaxentan—EDNRB—Signaling Pathways—LRP6—osteoporosis	0.000202	0.00301	CbGpPWpGaD
Sitaxentan—CYP2C19—Metapathway biotransformation—CYP27A1—osteoporosis	0.000201	0.00301	CbGpPWpGaD
Sitaxentan—EDNRB—Signaling by GPCR—PTHLH—osteoporosis	0.0002	0.00299	CbGpPWpGaD
Sitaxentan—EDNRA—Signaling Pathways—PTH1R—osteoporosis	0.000195	0.00291	CbGpPWpGaD
Sitaxentan—EDNRA—Signaling Pathways—CALCR—osteoporosis	0.000195	0.00291	CbGpPWpGaD
Sitaxentan—EDNRB—GPCR downstream signaling—CALCA—osteoporosis	0.000194	0.0029	CbGpPWpGaD
Sitaxentan—Body temperature increased—Estropipate—osteoporosis	0.000192	0.000496	CcSEcCtD
Sitaxentan—Feeling abnormal—Ibandronate—osteoporosis	0.000192	0.000496	CcSEcCtD
Sitaxentan—Tremor—Zoledronate—osteoporosis	0.000192	0.000495	CcSEcCtD
Sitaxentan—Skin disorder—Ethinyl Estradiol—osteoporosis	0.000192	0.000494	CcSEcCtD
Sitaxentan—Nervousness—Conjugated Estrogens—osteoporosis	0.000191	0.000494	CcSEcCtD
Sitaxentan—Infection—Risedronate—osteoporosis	0.000191	0.000493	CcSEcCtD
Sitaxentan—Hepatobiliary disease—Estradiol—osteoporosis	0.000191	0.000492	CcSEcCtD
Sitaxentan—EDNRA—GPCR downstream signaling—PTH—osteoporosis	0.000191	0.00285	CbGpPWpGaD
Sitaxentan—Urticaria—Alendronate—osteoporosis	0.00019	0.000491	CcSEcCtD
Sitaxentan—Epistaxis—Estradiol—osteoporosis	0.00019	0.000491	CcSEcCtD
Sitaxentan—Ill-defined disorder—Zoledronate—osteoporosis	0.00019	0.00049	CcSEcCtD
Sitaxentan—Body temperature increased—Alendronate—osteoporosis	0.000189	0.000489	CcSEcCtD
Sitaxentan—Muscle spasms—Conjugated Estrogens—osteoporosis	0.000189	0.000489	CcSEcCtD
Sitaxentan—Sinusitis—Estradiol—osteoporosis	0.000189	0.000488	CcSEcCtD
Sitaxentan—Anaemia—Zoledronate—osteoporosis	0.000189	0.000488	CcSEcCtD
Sitaxentan—Nervous system disorder—Risedronate—osteoporosis	0.000189	0.000487	CcSEcCtD
Sitaxentan—Discomfort—Pamidronate—osteoporosis	0.000188	0.000486	CcSEcCtD
Sitaxentan—Agitation—Zoledronate—osteoporosis	0.000188	0.000485	CcSEcCtD
Sitaxentan—Skin disorder—Risedronate—osteoporosis	0.000187	0.000482	CcSEcCtD
Sitaxentan—Body temperature increased—Raloxifene—osteoporosis	0.000186	0.000481	CcSEcCtD
Sitaxentan—CYP2C9—Biological oxidations—CYP27A1—osteoporosis	0.000186	0.00278	CbGpPWpGaD
Sitaxentan—EDNRA—GPCR downstream signaling—CNR2—osteoporosis	0.000186	0.00278	CbGpPWpGaD
Sitaxentan—Urticaria—Ibandronate—osteoporosis	0.000185	0.000478	CcSEcCtD
Sitaxentan—CYP3A4—Tryptophan metabolism—CYP19A1—osteoporosis	0.000185	0.00277	CbGpPWpGaD
Sitaxentan—Malaise—Zoledronate—osteoporosis	0.000185	0.000476	CcSEcCtD
Sitaxentan—Body temperature increased—Ibandronate—osteoporosis	0.000184	0.000476	CcSEcCtD
Sitaxentan—Confusional state—Pamidronate—osteoporosis	0.000184	0.000476	CcSEcCtD
Sitaxentan—CYP2C9—Phase 1 - Functionalization of compounds—CYP19A1—osteoporosis	0.000184	0.00275	CbGpPWpGaD
Sitaxentan—Vertigo—Zoledronate—osteoporosis	0.000184	0.000474	CcSEcCtD
Sitaxentan—CYP2C9—Metapathway biotransformation—CYP27A1—osteoporosis	0.000183	0.00274	CbGpPWpGaD
Sitaxentan—Leukopenia—Zoledronate—osteoporosis	0.000183	0.000473	CcSEcCtD
Sitaxentan—Oedema—Pamidronate—osteoporosis	0.000183	0.000472	CcSEcCtD
Sitaxentan—Haemoglobin—Estradiol—osteoporosis	0.000182	0.00047	CcSEcCtD
Sitaxentan—Infection—Pamidronate—osteoporosis	0.000182	0.000469	CcSEcCtD
Sitaxentan—Rhinitis—Estradiol—osteoporosis	0.000182	0.000469	CcSEcCtD
Sitaxentan—Urticaria—Calcitriol—osteoporosis	0.000181	0.000468	CcSEcCtD
Sitaxentan—Haemorrhage—Estradiol—osteoporosis	0.000181	0.000467	CcSEcCtD
Sitaxentan—Hepatitis—Estradiol—osteoporosis	0.000181	0.000467	CcSEcCtD
Sitaxentan—Body temperature increased—Calcitriol—osteoporosis	0.000181	0.000466	CcSEcCtD
Sitaxentan—EDNRB—GPCR ligand binding—POMC—osteoporosis	0.00018	0.00269	CbGpPWpGaD
Sitaxentan—Hypersensitivity—Estropipate—osteoporosis	0.000179	0.000463	CcSEcCtD
Sitaxentan—Nervous system disorder—Pamidronate—osteoporosis	0.000179	0.000463	CcSEcCtD
Sitaxentan—Thrombocytopenia—Pamidronate—osteoporosis	0.000179	0.000462	CcSEcCtD
Sitaxentan—Urinary tract disorder—Estradiol—osteoporosis	0.000179	0.000462	CcSEcCtD
Sitaxentan—Vomiting—Etidronic acid—osteoporosis	0.000179	0.000461	CcSEcCtD
Sitaxentan—Oedema peripheral—Estradiol—osteoporosis	0.000178	0.00046	CcSEcCtD
Sitaxentan—Tachycardia—Pamidronate—osteoporosis	0.000178	0.00046	CcSEcCtD
Sitaxentan—Urethral disorder—Estradiol—osteoporosis	0.000178	0.000458	CcSEcCtD
Sitaxentan—Rash—Etidronic acid—osteoporosis	0.000177	0.000458	CcSEcCtD
Sitaxentan—Dermatitis—Etidronic acid—osteoporosis	0.000177	0.000457	CcSEcCtD
Sitaxentan—Vertigo—Conjugated Estrogens—osteoporosis	0.000177	0.000457	CcSEcCtD
Sitaxentan—Hypersensitivity—Alendronate—osteoporosis	0.000177	0.000456	CcSEcCtD
Sitaxentan—EDNRB—Signaling by GPCR—CALCA—osteoporosis	0.000176	0.00264	CbGpPWpGaD
Sitaxentan—Headache—Etidronic acid—osteoporosis	0.000176	0.000455	CcSEcCtD
Sitaxentan—Asthenia—Estropipate—osteoporosis	0.000175	0.00045	CcSEcCtD
Sitaxentan—Visual impairment—Estradiol—osteoporosis	0.000175	0.00045	CcSEcCtD
Sitaxentan—Anorexia—Pamidronate—osteoporosis	0.000174	0.00045	CcSEcCtD
Sitaxentan—Chest pain—Zoledronate—osteoporosis	0.000174	0.000449	CcSEcCtD
Sitaxentan—Insomnia—Risedronate—osteoporosis	0.000174	0.000449	CcSEcCtD
Sitaxentan—EDNRA—Signaling by GPCR—PTH—osteoporosis	0.000173	0.00259	CbGpPWpGaD
Sitaxentan—Unspecified disorder of skin and subcutaneous tissue—Zoledronate—osteoporosis	0.000173	0.000446	CcSEcCtD
Sitaxentan—Discomfort—Zoledronate—osteoporosis	0.000172	0.000444	CcSEcCtD
Sitaxentan—Asthenia—Alendronate—osteoporosis	0.000172	0.000444	CcSEcCtD
Sitaxentan—Hypersensitivity—Ibandronate—osteoporosis	0.000172	0.000444	CcSEcCtD
Sitaxentan—Hypotension—Pamidronate—osteoporosis	0.000171	0.000441	CcSEcCtD
Sitaxentan—Dry mouth—Zoledronate—osteoporosis	0.00017	0.00044	CcSEcCtD
Sitaxentan—EDNRB—Signaling Pathways—TLN1—osteoporosis	0.00017	0.00254	CbGpPWpGaD
Sitaxentan—Gastrointestinal disorder—Ethinyl Estradiol—osteoporosis	0.00017	0.000439	CcSEcCtD
Sitaxentan—Fatigue—Ethinyl Estradiol—osteoporosis	0.00017	0.000439	CcSEcCtD
Sitaxentan—Dyspepsia—Risedronate—osteoporosis	0.000169	0.000437	CcSEcCtD
Sitaxentan—Eye disorder—Estradiol—osteoporosis	0.000169	0.000437	CcSEcCtD
Sitaxentan—EDNRA—Class A/1 (Rhodopsin-like receptors)—POMC—osteoporosis	0.000169	0.00253	CbGpPWpGaD
Sitaxentan—Tinnitus—Estradiol—osteoporosis	0.000169	0.000436	CcSEcCtD
Sitaxentan—EDNRA—Signaling by GPCR—CNR2—osteoporosis	0.000169	0.00252	CbGpPWpGaD
Sitaxentan—Constipation—Ethinyl Estradiol—osteoporosis	0.000169	0.000435	CcSEcCtD
Sitaxentan—Confusional state—Zoledronate—osteoporosis	0.000168	0.000434	CcSEcCtD
Sitaxentan—Hypersensitivity—Calcitriol—osteoporosis	0.000168	0.000434	CcSEcCtD
Sitaxentan—Flushing—Estradiol—osteoporosis	0.000168	0.000434	CcSEcCtD
Sitaxentan—Cardiac disorder—Estradiol—osteoporosis	0.000168	0.000434	CcSEcCtD
Sitaxentan—Chest pain—Conjugated Estrogens—osteoporosis	0.000168	0.000433	CcSEcCtD
Sitaxentan—Asthenia—Ibandronate—osteoporosis	0.000167	0.000432	CcSEcCtD
Sitaxentan—Nausea—Etidronic acid—osteoporosis	0.000167	0.000431	CcSEcCtD
Sitaxentan—Oedema—Zoledronate—osteoporosis	0.000167	0.000431	CcSEcCtD
Sitaxentan—Unspecified disorder of skin and subcutaneous tissue—Conjugated Estrogens—osteoporosis	0.000167	0.00043	CcSEcCtD
Sitaxentan—Diarrhoea—Estropipate—osteoporosis	0.000167	0.00043	CcSEcCtD
Sitaxentan—Gastrointestinal disorder—Risedronate—osteoporosis	0.000166	0.000428	CcSEcCtD
Sitaxentan—Infection—Zoledronate—osteoporosis	0.000166	0.000428	CcSEcCtD
Sitaxentan—Fatigue—Risedronate—osteoporosis	0.000166	0.000428	CcSEcCtD
Sitaxentan—Insomnia—Pamidronate—osteoporosis	0.000165	0.000427	CcSEcCtD
Sitaxentan—Pain—Risedronate—osteoporosis	0.000164	0.000424	CcSEcCtD
Sitaxentan—Constipation—Risedronate—osteoporosis	0.000164	0.000424	CcSEcCtD
Sitaxentan—Angiopathy—Estradiol—osteoporosis	0.000164	0.000424	CcSEcCtD
Sitaxentan—Diarrhoea—Alendronate—osteoporosis	0.000164	0.000423	CcSEcCtD
Sitaxentan—Asthenia—Calcitriol—osteoporosis	0.000164	0.000423	CcSEcCtD
Sitaxentan—Nervous system disorder—Zoledronate—osteoporosis	0.000164	0.000423	CcSEcCtD
Sitaxentan—Immune system disorder—Estradiol—osteoporosis	0.000164	0.000422	CcSEcCtD
Sitaxentan—Thrombocytopenia—Zoledronate—osteoporosis	0.000164	0.000422	CcSEcCtD
Sitaxentan—Mediastinal disorder—Estradiol—osteoporosis	0.000163	0.000421	CcSEcCtD
Sitaxentan—Tachycardia—Zoledronate—osteoporosis	0.000163	0.000421	CcSEcCtD
Sitaxentan—Feeling abnormal—Ethinyl Estradiol—osteoporosis	0.000163	0.000419	CcSEcCtD
Sitaxentan—Somnolence—Pamidronate—osteoporosis	0.000163	0.000419	CcSEcCtD
Sitaxentan—Skin disorder—Zoledronate—osteoporosis	0.000162	0.000419	CcSEcCtD
Sitaxentan—Diarrhoea—Raloxifene—osteoporosis	0.000161	0.000416	CcSEcCtD
Sitaxentan—Dyspepsia—Pamidronate—osteoporosis	0.000161	0.000415	CcSEcCtD
Sitaxentan—Dizziness—Estropipate—osteoporosis	0.000161	0.000415	CcSEcCtD
Sitaxentan—Oedema—Conjugated Estrogens—osteoporosis	0.000161	0.000415	CcSEcCtD
Sitaxentan—Alopecia—Estradiol—osteoporosis	0.00016	0.000413	CcSEcCtD
Sitaxentan—Infection—Conjugated Estrogens—osteoporosis	0.00016	0.000412	CcSEcCtD
Sitaxentan—Diarrhoea—Ibandronate—osteoporosis	0.00016	0.000412	CcSEcCtD
Sitaxentan—Anorexia—Zoledronate—osteoporosis	0.000159	0.000411	CcSEcCtD
Sitaxentan—Decreased appetite—Pamidronate—osteoporosis	0.000159	0.00041	CcSEcCtD
Sitaxentan—Mental disorder—Estradiol—osteoporosis	0.000159	0.000409	CcSEcCtD
Sitaxentan—EDNRA—Signaling by GPCR—WNT1—osteoporosis	0.000159	0.00237	CbGpPWpGaD
Sitaxentan—Dizziness—Alendronate—osteoporosis	0.000159	0.000409	CcSEcCtD
Sitaxentan—EDNRA—GPCR downstream signaling—PTHLH—osteoporosis	0.000158	0.00236	CbGpPWpGaD
Sitaxentan—Gastrointestinal disorder—Pamidronate—osteoporosis	0.000158	0.000407	CcSEcCtD
Sitaxentan—Nervous system disorder—Conjugated Estrogens—osteoporosis	0.000158	0.000407	CcSEcCtD
Sitaxentan—Malnutrition—Estradiol—osteoporosis	0.000158	0.000407	CcSEcCtD
Sitaxentan—Fatigue—Pamidronate—osteoporosis	0.000158	0.000407	CcSEcCtD
Sitaxentan—Tachycardia—Conjugated Estrogens—osteoporosis	0.000157	0.000405	CcSEcCtD
Sitaxentan—Urticaria—Ethinyl Estradiol—osteoporosis	0.000157	0.000404	CcSEcCtD
Sitaxentan—Pain—Pamidronate—osteoporosis	0.000156	0.000403	CcSEcCtD
Sitaxentan—Constipation—Pamidronate—osteoporosis	0.000156	0.000403	CcSEcCtD
Sitaxentan—Diarrhoea—Calcitriol—osteoporosis	0.000156	0.000403	CcSEcCtD
Sitaxentan—Skin disorder—Conjugated Estrogens—osteoporosis	0.000156	0.000403	CcSEcCtD
Sitaxentan—Hypotension—Zoledronate—osteoporosis	0.000156	0.000403	CcSEcCtD
Sitaxentan—Body temperature increased—Ethinyl Estradiol—osteoporosis	0.000156	0.000402	CcSEcCtD
Sitaxentan—Dizziness—Raloxifene—osteoporosis	0.000156	0.000402	CcSEcCtD
Sitaxentan—Tension—Estradiol—osteoporosis	0.000155	0.000399	CcSEcCtD
Sitaxentan—Vomiting—Estropipate—osteoporosis	0.000155	0.000399	CcSEcCtD
Sitaxentan—EDNRA—Signaling Pathways—MGLL—osteoporosis	0.000155	0.00231	CbGpPWpGaD
Sitaxentan—Dizziness—Ibandronate—osteoporosis	0.000154	0.000398	CcSEcCtD
Sitaxentan—Rash—Estropipate—osteoporosis	0.000153	0.000396	CcSEcCtD
Sitaxentan—Dermatitis—Estropipate—osteoporosis	0.000153	0.000396	CcSEcCtD
Sitaxentan—Anorexia—Conjugated Estrogens—osteoporosis	0.000153	0.000395	CcSEcCtD
Sitaxentan—Nervousness—Estradiol—osteoporosis	0.000153	0.000395	CcSEcCtD
Sitaxentan—Urticaria—Risedronate—osteoporosis	0.000153	0.000394	CcSEcCtD
Sitaxentan—Headache—Estropipate—osteoporosis	0.000152	0.000393	CcSEcCtD
Sitaxentan—Vomiting—Alendronate—osteoporosis	0.000152	0.000393	CcSEcCtD
Sitaxentan—Body temperature increased—Risedronate—osteoporosis	0.000152	0.000392	CcSEcCtD
Sitaxentan—Muscle spasms—Estradiol—osteoporosis	0.000152	0.000391	CcSEcCtD
Sitaxentan—Rash—Alendronate—osteoporosis	0.000151	0.00039	CcSEcCtD
Sitaxentan—Insomnia—Zoledronate—osteoporosis	0.000151	0.00039	CcSEcCtD
Sitaxentan—Dermatitis—Alendronate—osteoporosis	0.000151	0.00039	CcSEcCtD
Sitaxentan—EDNRA—Signaling Pathways—LRP5—osteoporosis	0.000151	0.00226	CbGpPWpGaD
Sitaxentan—Feeling abnormal—Pamidronate—osteoporosis	0.000151	0.000389	CcSEcCtD
Sitaxentan—Hypotension—Conjugated Estrogens—osteoporosis	0.00015	0.000388	CcSEcCtD
Sitaxentan—Headache—Alendronate—osteoporosis	0.00015	0.000387	CcSEcCtD
Sitaxentan—Vomiting—Raloxifene—osteoporosis	0.00015	0.000387	CcSEcCtD
Sitaxentan—CYP3A4—Cytochrome P450 - arranged by substrate type—CYP19A1—osteoporosis	0.00015	0.00224	CbGpPWpGaD
Sitaxentan—CYP2C19—Cytochrome P450 - arranged by substrate type—POMC—osteoporosis	0.00015	0.00223	CbGpPWpGaD
Sitaxentan—Rash—Raloxifene—osteoporosis	0.000149	0.000383	CcSEcCtD
Sitaxentan—Dermatitis—Raloxifene—osteoporosis	0.000148	0.000383	CcSEcCtD
Sitaxentan—Somnolence—Zoledronate—osteoporosis	0.000148	0.000383	CcSEcCtD
Sitaxentan—Vomiting—Ibandronate—osteoporosis	0.000148	0.000383	CcSEcCtD
Sitaxentan—Tremor—Estradiol—osteoporosis	0.000148	0.000381	CcSEcCtD
Sitaxentan—CYP3A4—Oxidation by Cytochrome P450—CYP19A1—osteoporosis	0.000148	0.00221	CbGpPWpGaD
Sitaxentan—Headache—Raloxifene—osteoporosis	0.000148	0.000381	CcSEcCtD
Sitaxentan—Rash—Ibandronate—osteoporosis	0.000147	0.00038	CcSEcCtD
Sitaxentan—Dermatitis—Ibandronate—osteoporosis	0.000147	0.000379	CcSEcCtD
Sitaxentan—Dyspepsia—Zoledronate—osteoporosis	0.000147	0.000379	CcSEcCtD
Sitaxentan—EDNRB—Signaling Pathways—P4HB—osteoporosis	0.000147	0.00219	CbGpPWpGaD
Sitaxentan—Ill-defined disorder—Estradiol—osteoporosis	0.000146	0.000377	CcSEcCtD
Sitaxentan—Headache—Ibandronate—osteoporosis	0.000146	0.000377	CcSEcCtD
Sitaxentan—Insomnia—Conjugated Estrogens—osteoporosis	0.000145	0.000375	CcSEcCtD
Sitaxentan—Hypersensitivity—Ethinyl Estradiol—osteoporosis	0.000145	0.000375	CcSEcCtD
Sitaxentan—Vomiting—Calcitriol—osteoporosis	0.000145	0.000375	CcSEcCtD
Sitaxentan—Decreased appetite—Zoledronate—osteoporosis	0.000145	0.000375	CcSEcCtD
Sitaxentan—Agitation—Estradiol—osteoporosis	0.000145	0.000374	CcSEcCtD
Sitaxentan—Nausea—Estropipate—osteoporosis	0.000145	0.000373	CcSEcCtD
Sitaxentan—Body temperature increased—Pamidronate—osteoporosis	0.000145	0.000373	CcSEcCtD
Sitaxentan—EDNRA—Signaling Pathways—LRP6—osteoporosis	0.000144	0.00216	CbGpPWpGaD
Sitaxentan—Gastrointestinal disorder—Zoledronate—osteoporosis	0.000144	0.000372	CcSEcCtD
Sitaxentan—Rash—Calcitriol—osteoporosis	0.000144	0.000372	CcSEcCtD
Sitaxentan—Fatigue—Zoledronate—osteoporosis	0.000144	0.000371	CcSEcCtD
Sitaxentan—Dermatitis—Calcitriol—osteoporosis	0.000144	0.000371	CcSEcCtD
Sitaxentan—EDNRA—Signaling by GPCR—PTHLH—osteoporosis	0.000143	0.00214	CbGpPWpGaD
Sitaxentan—Headache—Calcitriol—osteoporosis	0.000143	0.000369	CcSEcCtD
Sitaxentan—Somnolence—Conjugated Estrogens—osteoporosis	0.000143	0.000369	CcSEcCtD
Sitaxentan—EDNRB—Signaling Pathways—PTH—osteoporosis	0.000143	0.00213	CbGpPWpGaD
Sitaxentan—Constipation—Zoledronate—osteoporosis	0.000143	0.000368	CcSEcCtD
Sitaxentan—Pain—Zoledronate—osteoporosis	0.000143	0.000368	CcSEcCtD
Sitaxentan—Nausea—Alendronate—osteoporosis	0.000142	0.000367	CcSEcCtD
Sitaxentan—Malaise—Estradiol—osteoporosis	0.000142	0.000367	CcSEcCtD
Sitaxentan—Hypersensitivity—Risedronate—osteoporosis	0.000142	0.000366	CcSEcCtD
Sitaxentan—Vertigo—Estradiol—osteoporosis	0.000142	0.000366	CcSEcCtD
Sitaxentan—Dyspepsia—Conjugated Estrogens—osteoporosis	0.000142	0.000365	CcSEcCtD
Sitaxentan—Asthenia—Ethinyl Estradiol—osteoporosis	0.000142	0.000365	CcSEcCtD
Sitaxentan—EDNRB—Signaling Pathways—RAP1A—osteoporosis	0.00014	0.0021	CbGpPWpGaD
Sitaxentan—Nausea—Raloxifene—osteoporosis	0.00014	0.000361	CcSEcCtD
Sitaxentan—Decreased appetite—Conjugated Estrogens—osteoporosis	0.00014	0.000361	CcSEcCtD
Sitaxentan—EDNRB—Signaling Pathways—CNR2—osteoporosis	0.000139	0.00208	CbGpPWpGaD
Sitaxentan—EDNRA—GPCR downstream signaling—CALCA—osteoporosis	0.000139	0.00208	CbGpPWpGaD
Sitaxentan—Gastrointestinal disorder—Conjugated Estrogens—osteoporosis	0.000139	0.000358	CcSEcCtD
Sitaxentan—Fatigue—Conjugated Estrogens—osteoporosis	0.000139	0.000358	CcSEcCtD
Sitaxentan—EDNRB—Gastrin-CREB signalling pathway via PKC and MAPK—IL6—osteoporosis	0.000139	0.00207	CbGpPWpGaD
Sitaxentan—Nausea—Ibandronate—osteoporosis	0.000139	0.000358	CcSEcCtD
Sitaxentan—EDNRB—GPCR downstream signaling—ADCY5—osteoporosis	0.000138	0.00206	CbGpPWpGaD
Sitaxentan—Asthenia—Risedronate—osteoporosis	0.000138	0.000356	CcSEcCtD
Sitaxentan—Feeling abnormal—Zoledronate—osteoporosis	0.000138	0.000355	CcSEcCtD
Sitaxentan—Constipation—Conjugated Estrogens—osteoporosis	0.000138	0.000355	CcSEcCtD
Sitaxentan—Pain—Conjugated Estrogens—osteoporosis	0.000138	0.000355	CcSEcCtD
Sitaxentan—EDNRB—Signaling Pathways—NFATC1—osteoporosis	0.000137	0.00205	CbGpPWpGaD
Sitaxentan—CYP2C19—Metabolism of lipids and lipoproteins—FDPS—osteoporosis	0.000136	0.00204	CbGpPWpGaD
Sitaxentan—CYP2C9—Cytochrome P450 - arranged by substrate type—POMC—osteoporosis	0.000136	0.00204	CbGpPWpGaD
Sitaxentan—EDNRB—Signaling Pathways—DKK1—osteoporosis	0.000136	0.00203	CbGpPWpGaD
Sitaxentan—Nausea—Calcitriol—osteoporosis	0.000136	0.00035	CcSEcCtD
Sitaxentan—Diarrhoea—Ethinyl Estradiol—osteoporosis	0.000135	0.000348	CcSEcCtD
Sitaxentan—Hypersensitivity—Pamidronate—osteoporosis	0.000135	0.000348	CcSEcCtD
Sitaxentan—Chest pain—Estradiol—osteoporosis	0.000134	0.000346	CcSEcCtD
Sitaxentan—Unspecified disorder of skin and subcutaneous tissue—Estradiol—osteoporosis	0.000133	0.000344	CcSEcCtD
Sitaxentan—Urticaria—Zoledronate—osteoporosis	0.000133	0.000342	CcSEcCtD
Sitaxentan—Discomfort—Estradiol—osteoporosis	0.000133	0.000342	CcSEcCtD
Sitaxentan—Body temperature increased—Zoledronate—osteoporosis	0.000132	0.000341	CcSEcCtD
Sitaxentan—Diarrhoea—Risedronate—osteoporosis	0.000132	0.00034	CcSEcCtD
Sitaxentan—Dry mouth—Estradiol—osteoporosis	0.000131	0.000339	CcSEcCtD
Sitaxentan—Asthenia—Pamidronate—osteoporosis	0.000131	0.000338	CcSEcCtD
Sitaxentan—EDNRB—Signaling Pathways—WNT1—osteoporosis	0.000131	0.00196	CbGpPWpGaD
Sitaxentan—Dizziness—Ethinyl Estradiol—osteoporosis	0.00013	0.000337	CcSEcCtD
Sitaxentan—Confusional state—Estradiol—osteoporosis	0.00013	0.000335	CcSEcCtD
Sitaxentan—CYP2C19—Metabolism of lipids and lipoproteins—GPD2—osteoporosis	0.000129	0.00193	CbGpPWpGaD
Sitaxentan—EDNRA—GPCR ligand binding—POMC—osteoporosis	0.000129	0.00192	CbGpPWpGaD
Sitaxentan—Oedema—Estradiol—osteoporosis	0.000129	0.000332	CcSEcCtD
Sitaxentan—Infection—Estradiol—osteoporosis	0.000128	0.00033	CcSEcCtD
Sitaxentan—Urticaria—Conjugated Estrogens—osteoporosis	0.000128	0.00033	CcSEcCtD
Sitaxentan—EDNRB—Signaling Pathways—FGA—osteoporosis	0.000127	0.0019	CbGpPWpGaD
Sitaxentan—Dizziness—Risedronate—osteoporosis	0.000127	0.000328	CcSEcCtD
Sitaxentan—Body temperature increased—Conjugated Estrogens—osteoporosis	0.000127	0.000328	CcSEcCtD
Sitaxentan—EDNRA—Signaling by GPCR—CALCA—osteoporosis	0.000126	0.00189	CbGpPWpGaD
Sitaxentan—Nervous system disorder—Estradiol—osteoporosis	0.000126	0.000326	CcSEcCtD
Sitaxentan—Tachycardia—Estradiol—osteoporosis	0.000126	0.000324	CcSEcCtD
Sitaxentan—EDNRB—Signaling by GPCR—ADCY5—osteoporosis	0.000126	0.00188	CbGpPWpGaD
Sitaxentan—Vomiting—Ethinyl Estradiol—osteoporosis	0.000125	0.000324	CcSEcCtD
Sitaxentan—Diarrhoea—Pamidronate—osteoporosis	0.000125	0.000323	CcSEcCtD
Sitaxentan—Skin disorder—Estradiol—osteoporosis	0.000125	0.000323	CcSEcCtD
Sitaxentan—Rash—Ethinyl Estradiol—osteoporosis	0.000124	0.000321	CcSEcCtD
Sitaxentan—CYP2C9—Metabolism of lipids and lipoproteins—FDPS—osteoporosis	0.000124	0.00186	CbGpPWpGaD
Sitaxentan—Dermatitis—Ethinyl Estradiol—osteoporosis	0.000124	0.000321	CcSEcCtD
Sitaxentan—Headache—Ethinyl Estradiol—osteoporosis	0.000124	0.000319	CcSEcCtD
Sitaxentan—Hypersensitivity—Zoledronate—osteoporosis	0.000123	0.000317	CcSEcCtD
Sitaxentan—CYP3A4—Biological oxidations—CYP27A1—osteoporosis	0.000123	0.00183	CbGpPWpGaD
Sitaxentan—Vomiting—Risedronate—osteoporosis	0.000122	0.000316	CcSEcCtD
Sitaxentan—EDNRA—Signaling Pathways—TLN1—osteoporosis	0.000122	0.00182	CbGpPWpGaD
Sitaxentan—CYP3A4—Phase 1 - Functionalization of compounds—CYP19A1—osteoporosis	0.000121	0.00181	CbGpPWpGaD
Sitaxentan—Rash—Risedronate—osteoporosis	0.000121	0.000313	CcSEcCtD
Sitaxentan—CYP2C19—Phase 1 - Functionalization of compounds—POMC—osteoporosis	0.000121	0.00181	CbGpPWpGaD
Sitaxentan—Dermatitis—Risedronate—osteoporosis	0.000121	0.000313	CcSEcCtD
Sitaxentan—CYP3A4—Metapathway biotransformation—CYP27A1—osteoporosis	0.000121	0.00181	CbGpPWpGaD
Sitaxentan—Dizziness—Pamidronate—osteoporosis	0.000121	0.000312	CcSEcCtD
Sitaxentan—Headache—Risedronate—osteoporosis	0.00012	0.000311	CcSEcCtD
Sitaxentan—Asthenia—Zoledronate—osteoporosis	0.00012	0.000309	CcSEcCtD
Sitaxentan—Hypersensitivity—Conjugated Estrogens—osteoporosis	0.000118	0.000306	CcSEcCtD
Sitaxentan—EDNRB—Signaling Pathways—PTHLH—osteoporosis	0.000118	0.00177	CbGpPWpGaD
Sitaxentan—EDNRB—Signaling Pathways—BMP2—osteoporosis	0.000118	0.00177	CbGpPWpGaD
Sitaxentan—CYP2C9—Metabolism of lipids and lipoproteins—GPD2—osteoporosis	0.000118	0.00176	CbGpPWpGaD
Sitaxentan—Nausea—Ethinyl Estradiol—osteoporosis	0.000117	0.000302	CcSEcCtD
Sitaxentan—Insomnia—Estradiol—osteoporosis	0.000116	0.0003	CcSEcCtD
Sitaxentan—Vomiting—Pamidronate—osteoporosis	0.000116	0.0003	CcSEcCtD
Sitaxentan—EDNRB—Signaling Pathways—FGB—osteoporosis	0.000116	0.00173	CbGpPWpGaD
Sitaxentan—Asthenia—Conjugated Estrogens—osteoporosis	0.000115	0.000298	CcSEcCtD
Sitaxentan—Rash—Pamidronate—osteoporosis	0.000115	0.000297	CcSEcCtD
Sitaxentan—Dermatitis—Pamidronate—osteoporosis	0.000115	0.000297	CcSEcCtD
Sitaxentan—Headache—Pamidronate—osteoporosis	0.000115	0.000296	CcSEcCtD
Sitaxentan—Somnolence—Estradiol—osteoporosis	0.000114	0.000295	CcSEcCtD
Sitaxentan—Diarrhoea—Zoledronate—osteoporosis	0.000114	0.000295	CcSEcCtD
Sitaxentan—Nausea—Risedronate—osteoporosis	0.000114	0.000295	CcSEcCtD
Sitaxentan—Dyspepsia—Estradiol—osteoporosis	0.000113	0.000292	CcSEcCtD
Sitaxentan—Decreased appetite—Estradiol—osteoporosis	0.000112	0.000289	CcSEcCtD
Sitaxentan—EDNRB—Signaling Pathways—PSMA5—osteoporosis	0.000112	0.00167	CbGpPWpGaD
Sitaxentan—EDNRB—Signaling Pathways—PSMA2—osteoporosis	0.000112	0.00167	CbGpPWpGaD
Sitaxentan—Gastrointestinal disorder—Estradiol—osteoporosis	0.000111	0.000287	CcSEcCtD
Sitaxentan—Fatigue—Estradiol—osteoporosis	0.000111	0.000286	CcSEcCtD
Sitaxentan—CYP2C9—Phase 1 - Functionalization of compounds—POMC—osteoporosis	0.000111	0.00165	CbGpPWpGaD
Sitaxentan—Dizziness—Zoledronate—osteoporosis	0.00011	0.000285	CcSEcCtD
Sitaxentan—Constipation—Estradiol—osteoporosis	0.00011	0.000284	CcSEcCtD
Sitaxentan—Pain—Estradiol—osteoporosis	0.00011	0.000284	CcSEcCtD
Sitaxentan—Diarrhoea—Conjugated Estrogens—osteoporosis	0.00011	0.000284	CcSEcCtD
Sitaxentan—Nausea—Pamidronate—osteoporosis	0.000109	0.00028	CcSEcCtD
Sitaxentan—CYP2C19—Biological oxidations—CYP19A1—osteoporosis	0.000107	0.0016	CbGpPWpGaD
Sitaxentan—Dizziness—Conjugated Estrogens—osteoporosis	0.000106	0.000274	CcSEcCtD
Sitaxentan—Vomiting—Zoledronate—osteoporosis	0.000106	0.000274	CcSEcCtD
Sitaxentan—Feeling abnormal—Estradiol—osteoporosis	0.000106	0.000274	CcSEcCtD
Sitaxentan—CYP2C19—Metapathway biotransformation—CYP19A1—osteoporosis	0.000106	0.00158	CbGpPWpGaD
Sitaxentan—Rash—Zoledronate—osteoporosis	0.000105	0.000272	CcSEcCtD
Sitaxentan—Dermatitis—Zoledronate—osteoporosis	0.000105	0.000271	CcSEcCtD
Sitaxentan—EDNRA—Signaling Pathways—P4HB—osteoporosis	0.000105	0.00157	CbGpPWpGaD
Sitaxentan—Headache—Zoledronate—osteoporosis	0.000105	0.00027	CcSEcCtD
Sitaxentan—EDNRB—Signaling Pathways—CALCA—osteoporosis	0.000104	0.00156	CbGpPWpGaD
Sitaxentan—EDNRA—Signaling Pathways—PTH—osteoporosis	0.000102	0.00153	CbGpPWpGaD
Sitaxentan—Vomiting—Conjugated Estrogens—osteoporosis	0.000102	0.000264	CcSEcCtD
Sitaxentan—Urticaria—Estradiol—osteoporosis	0.000102	0.000264	CcSEcCtD
Sitaxentan—Body temperature increased—Estradiol—osteoporosis	0.000102	0.000262	CcSEcCtD
Sitaxentan—EDNRB—GPCR downstream signaling—POMC—osteoporosis	0.000102	0.00152	CbGpPWpGaD
Sitaxentan—Rash—Conjugated Estrogens—osteoporosis	0.000101	0.000262	CcSEcCtD
Sitaxentan—Dermatitis—Conjugated Estrogens—osteoporosis	0.000101	0.000261	CcSEcCtD
Sitaxentan—Headache—Conjugated Estrogens—osteoporosis	0.000101	0.00026	CcSEcCtD
Sitaxentan—CYP2C19—Metabolism of lipids and lipoproteins—OXCT1—osteoporosis	0.000101	0.0015	CbGpPWpGaD
Sitaxentan—EDNRA—Signaling Pathways—RAP1A—osteoporosis	0.000101	0.0015	CbGpPWpGaD
Sitaxentan—EDNRA—Signaling Pathways—CNR2—osteoporosis	9.97e-05	0.00149	CbGpPWpGaD
Sitaxentan—EDNRA—Gastrin-CREB signalling pathway via PKC and MAPK—IL6—osteoporosis	9.92e-05	0.00148	CbGpPWpGaD
Sitaxentan—Nausea—Zoledronate—osteoporosis	9.92e-05	0.000256	CcSEcCtD
Sitaxentan—EDNRA—GPCR downstream signaling—ADCY5—osteoporosis	9.89e-05	0.00148	CbGpPWpGaD
Sitaxentan—EDNRA—Signaling Pathways—NFATC1—osteoporosis	9.8e-05	0.00146	CbGpPWpGaD
Sitaxentan—CYP2C19—Metabolism of lipids and lipoproteins—MGLL—osteoporosis	9.8e-05	0.00146	CbGpPWpGaD
Sitaxentan—CYP2C9—Biological oxidations—CYP19A1—osteoporosis	9.77e-05	0.00146	CbGpPWpGaD
Sitaxentan—EDNRA—Signaling Pathways—DKK1—osteoporosis	9.73e-05	0.00145	CbGpPWpGaD
Sitaxentan—CYP2C9—Metapathway biotransformation—CYP19A1—osteoporosis	9.64e-05	0.00144	CbGpPWpGaD
Sitaxentan—Nausea—Conjugated Estrogens—osteoporosis	9.55e-05	0.000246	CcSEcCtD
Sitaxentan—Hypersensitivity—Estradiol—osteoporosis	9.48e-05	0.000245	CcSEcCtD
Sitaxentan—EDNRB—Signaling Pathways—KL—osteoporosis	9.47e-05	0.00141	CbGpPWpGaD
Sitaxentan—EDNRA—Signaling Pathways—WNT1—osteoporosis	9.37e-05	0.0014	CbGpPWpGaD
Sitaxentan—Asthenia—Estradiol—osteoporosis	9.23e-05	0.000238	CcSEcCtD
Sitaxentan—EDNRB—Signaling by GPCR—POMC—osteoporosis	9.23e-05	0.00138	CbGpPWpGaD
Sitaxentan—CYP2C9—Metabolism of lipids and lipoproteins—OXCT1—osteoporosis	9.17e-05	0.00137	CbGpPWpGaD
Sitaxentan—EDNRA—Signaling Pathways—FGA—osteoporosis	9.12e-05	0.00136	CbGpPWpGaD
Sitaxentan—EDNRB—Signaling by GPCR—IL6R—osteoporosis	9.01e-05	0.00135	CbGpPWpGaD
Sitaxentan—CYP3A4—Cytochrome P450 - arranged by substrate type—POMC—osteoporosis	8.99e-05	0.00134	CbGpPWpGaD
Sitaxentan—EDNRA—Signaling by GPCR—ADCY5—osteoporosis	8.98e-05	0.00134	CbGpPWpGaD
Sitaxentan—CYP2C9—Metabolism of lipids and lipoproteins—MGLL—osteoporosis	8.94e-05	0.00133	CbGpPWpGaD
Sitaxentan—Diarrhoea—Estradiol—osteoporosis	8.81e-05	0.000227	CcSEcCtD
Sitaxentan—Dizziness—Estradiol—osteoporosis	8.51e-05	0.00022	CcSEcCtD
Sitaxentan—EDNRA—Signaling Pathways—PTHLH—osteoporosis	8.47e-05	0.00127	CbGpPWpGaD
Sitaxentan—EDNRA—Signaling Pathways—BMP2—osteoporosis	8.47e-05	0.00127	CbGpPWpGaD
Sitaxentan—EDNRA—Signaling Pathways—FGB—osteoporosis	8.29e-05	0.00124	CbGpPWpGaD
Sitaxentan—Vomiting—Estradiol—osteoporosis	8.18e-05	0.000211	CcSEcCtD
Sitaxentan—Rash—Estradiol—osteoporosis	8.11e-05	0.000209	CcSEcCtD
Sitaxentan—Dermatitis—Estradiol—osteoporosis	8.11e-05	0.000209	CcSEcCtD
Sitaxentan—Headache—Estradiol—osteoporosis	8.06e-05	0.000208	CcSEcCtD
Sitaxentan—EDNRA—Signaling Pathways—PSMA5—osteoporosis	8.01e-05	0.0012	CbGpPWpGaD
Sitaxentan—EDNRA—Signaling Pathways—PSMA2—osteoporosis	8.01e-05	0.0012	CbGpPWpGaD
Sitaxentan—CYP2C19—Metabolism of lipids and lipoproteins—CYP27A1—osteoporosis	7.83e-05	0.00117	CbGpPWpGaD
Sitaxentan—Nausea—Estradiol—osteoporosis	7.64e-05	0.000197	CcSEcCtD
Sitaxentan—EDNRA—Signaling Pathways—CALCA—osteoporosis	7.46e-05	0.00111	CbGpPWpGaD
Sitaxentan—EDNRB—Signaling Pathways—ADCY5—osteoporosis	7.41e-05	0.00111	CbGpPWpGaD
Sitaxentan—CYP3A4—Phase 1 - Functionalization of compounds—POMC—osteoporosis	7.29e-05	0.00109	CbGpPWpGaD
Sitaxentan—EDNRA—GPCR downstream signaling—POMC—osteoporosis	7.28e-05	0.00109	CbGpPWpGaD
Sitaxentan—EDNRB—Signaling Pathways—SPP1—osteoporosis	7.17e-05	0.00107	CbGpPWpGaD
Sitaxentan—CYP2C9—Metabolism of lipids and lipoproteins—CYP27A1—osteoporosis	7.14e-05	0.00107	CbGpPWpGaD
Sitaxentan—EDNRA—Signaling Pathways—KL—osteoporosis	6.77e-05	0.00101	CbGpPWpGaD
Sitaxentan—CYP2C19—Metabolism of lipids and lipoproteins—P4HB—osteoporosis	6.66e-05	0.000995	CbGpPWpGaD
Sitaxentan—EDNRA—Signaling by GPCR—POMC—osteoporosis	6.61e-05	0.000987	CbGpPWpGaD
Sitaxentan—EDNRB—Signaling Pathways—IRS2—osteoporosis	6.49e-05	0.000969	CbGpPWpGaD
Sitaxentan—EDNRA—Signaling by GPCR—IL6R—osteoporosis	6.45e-05	0.000963	CbGpPWpGaD
Sitaxentan—CYP3A4—Biological oxidations—CYP19A1—osteoporosis	6.44e-05	0.000963	CbGpPWpGaD
Sitaxentan—CYP2C19—Biological oxidations—POMC—osteoporosis	6.44e-05	0.000962	CbGpPWpGaD
Sitaxentan—CYP3A4—Metapathway biotransformation—CYP19A1—osteoporosis	6.36e-05	0.000949	CbGpPWpGaD
Sitaxentan—EDNRB—Signaling Pathways—LEP—osteoporosis	6.35e-05	0.000948	CbGpPWpGaD
Sitaxentan—CYP2C19—Metabolism—PKM—osteoporosis	6.07e-05	0.000907	CbGpPWpGaD
Sitaxentan—CYP2C19—Metabolism—FDPS—osteoporosis	6.07e-05	0.000907	CbGpPWpGaD
Sitaxentan—CYP2C9—Metabolism of lipids and lipoproteins—P4HB—osteoporosis	6.07e-05	0.000907	CbGpPWpGaD
Sitaxentan—EDNRB—Signaling Pathways—ESR1—osteoporosis	6.06e-05	0.000905	CbGpPWpGaD
Sitaxentan—CYP2C9—Biological oxidations—POMC—osteoporosis	5.87e-05	0.000877	CbGpPWpGaD
Sitaxentan—CYP2C19—Metabolism—PGLS—osteoporosis	5.76e-05	0.00086	CbGpPWpGaD
Sitaxentan—CYP2C19—Metabolism—GPD2—osteoporosis	5.76e-05	0.00086	CbGpPWpGaD
Sitaxentan—EDNRB—Signaling Pathways—IRS1—osteoporosis	5.66e-05	0.000846	CbGpPWpGaD
Sitaxentan—CYP2C9—Metabolism—PKM—osteoporosis	5.54e-05	0.000827	CbGpPWpGaD
Sitaxentan—CYP2C9—Metabolism—FDPS—osteoporosis	5.54e-05	0.000827	CbGpPWpGaD
Sitaxentan—EDNRB—Signaling Pathways—POMC—osteoporosis	5.45e-05	0.000815	CbGpPWpGaD
Sitaxentan—EDNRB—Signaling Pathways—IL6R—osteoporosis	5.32e-05	0.000795	CbGpPWpGaD
Sitaxentan—EDNRA—Signaling Pathways—ADCY5—osteoporosis	5.31e-05	0.000793	CbGpPWpGaD
Sitaxentan—CYP2C19—Metabolism—PNP—osteoporosis	5.27e-05	0.000787	CbGpPWpGaD
Sitaxentan—CYP2C19—Metabolism—ATIC—osteoporosis	5.27e-05	0.000787	CbGpPWpGaD
Sitaxentan—CYP2C9—Metabolism—PGLS—osteoporosis	5.25e-05	0.000784	CbGpPWpGaD
Sitaxentan—CYP2C9—Metabolism—GPD2—osteoporosis	5.25e-05	0.000784	CbGpPWpGaD
Sitaxentan—EDNRB—Signaling Pathways—IGF1—osteoporosis	5.25e-05	0.000784	CbGpPWpGaD
Sitaxentan—EDNRA—Signaling Pathways—SPP1—osteoporosis	5.13e-05	0.000767	CbGpPWpGaD
Sitaxentan—CYP2C9—Metabolism—PNP—osteoporosis	4.8e-05	0.000717	CbGpPWpGaD
Sitaxentan—CYP2C9—Metabolism—ATIC—osteoporosis	4.8e-05	0.000717	CbGpPWpGaD
Sitaxentan—EDNRA—Signaling Pathways—IRS2—osteoporosis	4.64e-05	0.000694	CbGpPWpGaD
Sitaxentan—EDNRA—Signaling Pathways—LEP—osteoporosis	4.54e-05	0.000679	CbGpPWpGaD
Sitaxentan—CYP2C19—Metabolism—CA2—osteoporosis	4.48e-05	0.000669	CbGpPWpGaD
Sitaxentan—CYP2C19—Metabolism—OXCT1—osteoporosis	4.48e-05	0.000669	CbGpPWpGaD
Sitaxentan—CYP2C19—Metabolism—MGLL—osteoporosis	4.36e-05	0.000652	CbGpPWpGaD
Sitaxentan—EDNRA—Signaling Pathways—ESR1—osteoporosis	4.34e-05	0.000648	CbGpPWpGaD
Sitaxentan—CYP2C19—Metabolism of lipids and lipoproteins—CYP19A1—osteoporosis	4.12e-05	0.000615	CbGpPWpGaD
Sitaxentan—CYP2C9—Metabolism—OXCT1—osteoporosis	4.08e-05	0.00061	CbGpPWpGaD
Sitaxentan—CYP2C9—Metabolism—CA2—osteoporosis	4.08e-05	0.00061	CbGpPWpGaD
Sitaxentan—EDNRA—Signaling Pathways—IRS1—osteoporosis	4.05e-05	0.000606	CbGpPWpGaD
Sitaxentan—EDNRB—Signaling by GPCR—IL6—osteoporosis	4.01e-05	0.000599	CbGpPWpGaD
Sitaxentan—CYP2C9—Metabolism—MGLL—osteoporosis	3.98e-05	0.000594	CbGpPWpGaD
Sitaxentan—EDNRA—Signaling Pathways—POMC—osteoporosis	3.9e-05	0.000583	CbGpPWpGaD
Sitaxentan—CYP3A4—Biological oxidations—POMC—osteoporosis	3.87e-05	0.000579	CbGpPWpGaD
Sitaxentan—EDNRA—Signaling Pathways—IL6R—osteoporosis	3.81e-05	0.000569	CbGpPWpGaD
Sitaxentan—EDNRA—Signaling Pathways—IGF1—osteoporosis	3.75e-05	0.000561	CbGpPWpGaD
Sitaxentan—CYP2C9—Metabolism of lipids and lipoproteins—CYP19A1—osteoporosis	3.75e-05	0.000561	CbGpPWpGaD
Sitaxentan—CYP2C19—Metabolism—IDH2—osteoporosis	3.71e-05	0.000554	CbGpPWpGaD
Sitaxentan—CYP3A4—Metabolism—PKM—osteoporosis	3.65e-05	0.000546	CbGpPWpGaD
Sitaxentan—CYP3A4—Metabolism—FDPS—osteoporosis	3.65e-05	0.000546	CbGpPWpGaD
Sitaxentan—CYP2C19—Metabolism—CYP27A1—osteoporosis	3.49e-05	0.000521	CbGpPWpGaD
Sitaxentan—CYP3A4—Metabolism—GPD2—osteoporosis	3.46e-05	0.000517	CbGpPWpGaD
Sitaxentan—CYP3A4—Metabolism—PGLS—osteoporosis	3.46e-05	0.000517	CbGpPWpGaD
Sitaxentan—CYP2C19—Metabolism—ACP5—osteoporosis	3.39e-05	0.000507	CbGpPWpGaD
Sitaxentan—CYP2C9—Metabolism—IDH2—osteoporosis	3.38e-05	0.000505	CbGpPWpGaD
Sitaxentan—CYP2C19—Metabolism of lipids and lipoproteins—GPX1—osteoporosis	3.35e-05	0.000501	CbGpPWpGaD
Sitaxentan—CYP2C9—Metabolism—CYP27A1—osteoporosis	3.18e-05	0.000475	CbGpPWpGaD
Sitaxentan—CYP3A4—Metabolism—ATIC—osteoporosis	3.17e-05	0.000473	CbGpPWpGaD
Sitaxentan—CYP3A4—Metabolism—PNP—osteoporosis	3.17e-05	0.000473	CbGpPWpGaD
Sitaxentan—CYP2C19—Metabolism—TPI1—osteoporosis	3.16e-05	0.000471	CbGpPWpGaD
Sitaxentan—EDNRB—Signaling Pathways—MYC—osteoporosis	3.15e-05	0.000471	CbGpPWpGaD
Sitaxentan—EDNRB—Signaling Pathways—TGFB1—osteoporosis	3.15e-05	0.00047	CbGpPWpGaD
Sitaxentan—CYP2C9—Metabolism—ACP5—osteoporosis	3.09e-05	0.000462	CbGpPWpGaD
Sitaxentan—CYP2C9—Metabolism of lipids and lipoproteins—GPX1—osteoporosis	3.06e-05	0.000456	CbGpPWpGaD
Sitaxentan—CYP2C19—Metabolism—P4HB—osteoporosis	2.97e-05	0.000443	CbGpPWpGaD
Sitaxentan—CYP2C19—Metabolism—GAPDH—osteoporosis	2.91e-05	0.000435	CbGpPWpGaD
Sitaxentan—CYP2C9—Metabolism—TPI1—osteoporosis	2.88e-05	0.00043	CbGpPWpGaD
Sitaxentan—EDNRA—Signaling by GPCR—IL6—osteoporosis	2.87e-05	0.000429	CbGpPWpGaD
Sitaxentan—CYP2C19—Metabolism—RAP1A—osteoporosis	2.84e-05	0.000424	CbGpPWpGaD
Sitaxentan—CYP2C9—Metabolism—P4HB—osteoporosis	2.7e-05	0.000404	CbGpPWpGaD
Sitaxentan—CYP3A4—Metabolism—CA2—osteoporosis	2.69e-05	0.000402	CbGpPWpGaD
Sitaxentan—CYP3A4—Metabolism—OXCT1—osteoporosis	2.69e-05	0.000402	CbGpPWpGaD
Sitaxentan—CYP2C9—Metabolism—GAPDH—osteoporosis	2.66e-05	0.000397	CbGpPWpGaD
Sitaxentan—CYP3A4—Metabolism—MGLL—osteoporosis	2.62e-05	0.000392	CbGpPWpGaD
Sitaxentan—CYP2C9—Metabolism—RAP1A—osteoporosis	2.59e-05	0.000386	CbGpPWpGaD
Sitaxentan—CYP2C19—Metabolism of lipids and lipoproteins—POMC—osteoporosis	2.47e-05	0.000369	CbGpPWpGaD
Sitaxentan—EDNRB—Signaling Pathways—IL6—osteoporosis	2.37e-05	0.000354	CbGpPWpGaD
Sitaxentan—CYP2C19—Metabolism—ENO1—osteoporosis	2.29e-05	0.000342	CbGpPWpGaD
Sitaxentan—CYP2C19—Metabolism—PSMA2—osteoporosis	2.26e-05	0.000337	CbGpPWpGaD
Sitaxentan—CYP2C19—Metabolism—PSMA5—osteoporosis	2.26e-05	0.000337	CbGpPWpGaD
Sitaxentan—EDNRA—Signaling Pathways—MYC—osteoporosis	2.26e-05	0.000337	CbGpPWpGaD
Sitaxentan—CYP2C9—Metabolism of lipids and lipoproteins—POMC—osteoporosis	2.26e-05	0.000337	CbGpPWpGaD
Sitaxentan—EDNRA—Signaling Pathways—TGFB1—osteoporosis	2.25e-05	0.000336	CbGpPWpGaD
Sitaxentan—CYP3A4—Metabolism—IDH2—osteoporosis	2.23e-05	0.000333	CbGpPWpGaD
Sitaxentan—CYP3A4—Metabolism—CYP27A1—osteoporosis	2.1e-05	0.000313	CbGpPWpGaD
Sitaxentan—CYP2C9—Metabolism—ENO1—osteoporosis	2.09e-05	0.000312	CbGpPWpGaD
Sitaxentan—CYP2C9—Metabolism—PSMA2—osteoporosis	2.06e-05	0.000308	CbGpPWpGaD
Sitaxentan—CYP2C9—Metabolism—PSMA5—osteoporosis	2.06e-05	0.000308	CbGpPWpGaD
Sitaxentan—CYP3A4—Metabolism—ACP5—osteoporosis	2.04e-05	0.000305	CbGpPWpGaD
Sitaxentan—CYP3A4—Metabolism—TPI1—osteoporosis	1.9e-05	0.000283	CbGpPWpGaD
Sitaxentan—CYP2C19—Metabolism—CYP19A1—osteoporosis	1.83e-05	0.000274	CbGpPWpGaD
Sitaxentan—CYP3A4—Metabolism—P4HB—osteoporosis	1.78e-05	0.000266	CbGpPWpGaD
Sitaxentan—CYP3A4—Metabolism—GAPDH—osteoporosis	1.75e-05	0.000262	CbGpPWpGaD
Sitaxentan—CYP3A4—Metabolism—RAP1A—osteoporosis	1.71e-05	0.000255	CbGpPWpGaD
Sitaxentan—EDNRA—Signaling Pathways—IL6—osteoporosis	1.7e-05	0.000253	CbGpPWpGaD
Sitaxentan—CYP2C9—Metabolism—CYP19A1—osteoporosis	1.67e-05	0.00025	CbGpPWpGaD
Sitaxentan—CYP2C19—Metabolism—ADCY5—osteoporosis	1.5e-05	0.000224	CbGpPWpGaD
Sitaxentan—CYP2C19—Metabolism—GPX1—osteoporosis	1.49e-05	0.000223	CbGpPWpGaD
Sitaxentan—CYP3A4—Metabolism—ENO1—osteoporosis	1.38e-05	0.000206	CbGpPWpGaD
Sitaxentan—CYP2C19—Metabolism—MTHFR—osteoporosis	1.38e-05	0.000206	CbGpPWpGaD
Sitaxentan—CYP2C9—Metabolism—ADCY5—osteoporosis	1.37e-05	0.000204	CbGpPWpGaD
Sitaxentan—CYP2C9—Metabolism—GPX1—osteoporosis	1.36e-05	0.000203	CbGpPWpGaD
Sitaxentan—CYP3A4—Metabolism—PSMA2—osteoporosis	1.36e-05	0.000203	CbGpPWpGaD
Sitaxentan—CYP3A4—Metabolism—PSMA5—osteoporosis	1.36e-05	0.000203	CbGpPWpGaD
Sitaxentan—CYP2C9—Metabolism—MTHFR—osteoporosis	1.26e-05	0.000188	CbGpPWpGaD
Sitaxentan—CYP3A4—Metabolism—CYP19A1—osteoporosis	1.1e-05	0.000165	CbGpPWpGaD
Sitaxentan—CYP2C19—Metabolism—POMC—osteoporosis	1.1e-05	0.000165	CbGpPWpGaD
Sitaxentan—CYP2C9—Metabolism—POMC—osteoporosis	1e-05	0.00015	CbGpPWpGaD
Sitaxentan—CYP3A4—Metabolism—ADCY5—osteoporosis	9e-06	0.000135	CbGpPWpGaD
Sitaxentan—CYP3A4—Metabolism—GPX1—osteoporosis	8.97e-06	0.000134	CbGpPWpGaD
Sitaxentan—CYP3A4—Metabolism—MTHFR—osteoporosis	8.28e-06	0.000124	CbGpPWpGaD
Sitaxentan—CYP3A4—Metabolism—POMC—osteoporosis	6.62e-06	9.89e-05	CbGpPWpGaD
